Jasper Therapeutics, Inc. (JSPRW) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is bullish — 1 Buy.
Analysts estimate Earnings Per Share (EPS) of $-4.54 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.89 vs est $-4.54 (missed -7.8%). 2025: actual $-3.95 vs est $-4.71 (beat +16.2%). Analyst accuracy: 87%.
JSPRW Analyst Ratings
Buy
Based on 1 analysts giving stock ratings to Jasper Therapeutics, Inc. in the past 3 months
EPS Estimates — JSPRW
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.89
vs Est –$4.54
▼ 7.2% off
2025
Actual –$3.95
vs Est –$4.71
▲ 19.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — JSPRW
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
